UNSPSC 51161565: Acitazanolast hydrate

This classification denotes an anti-asthmatic agent with the molecular structure C9H7N5O3.H2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, U6SU9ZSU4K chemically known as acetic acid, 2-oxo-2-((3-(2h-tetrazol-5-yl)phenyl)amino)-, hydrate (1:1), but more commonly known as acitazanolast hydrate, which bears US NIH Compound Identifier 11954321. European Medicines Agency schedules Acitazanolast hydrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB33524.

Most nations, for tariff and trade purposes, schedule acitazanolast hydrate under HS 29339990. SMILES: C1CC(CC(C1)NC(=O)C(=O)O)C2[NH]NNN2.O.

UNSPSC 51161565 Acitazanolast hydrate is a Commodity code covering pharmaceutical active ingredients and finished dosage forms distributed through state and local healthcare systems. State and local governments procure generic pharmaceutical products and over-the-counter medications for use across health departments, correctional facilities, safety-net clinics, and other public health entities. The code captures both branded and generic versions of pharmaceutical compounds, though recent solicitations focus on generic multi-source products and OTC items available through established pharmaceutical distribution channels. Issuing bodies include state departments of administration and health, multistate cooperative purchasing alliances, and county and municipal health authorities, though the recent opportunities block shows concentrated activity through cooperative vehicles rather than individual jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for participating state and local government facilities across Minnesota, Oregon, and other member jurisdictions. The RFP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with award effective July 1, 2026 and a two-year initial term. Evaluation emphasizes price competitiveness (75 percent weight), with vendors required to certify cGMP and Drug Supply Chain Security Act compliance, maintain relationships with at least two of the three wholesalers, carry $5 million commercial general liability insurance, and accept a 3 percent administrative fee. No specific dollar values or set-aside designations were disclosed in the solicitation. The code shows limited recent activity in the state and local record, with the MMCAP RFP as the primary representative opportunity.